Report : Europe Upstream Bioprocessing Market Forecast to 2030 - Regional analysis - by Product Type (Bioreactors/Fermenters, Cell Culture, Filters, Bags and Containers, and Others), Workflow (Media Preparation, Cell Culture, and Cell Separation), Usage Type (Single-use and Multi-use), and Mode (In-house and Outsourced)
At 13.4% CAGR, Europe Upstream Bioprocessing Market is Projected to be Worth US$ 7,069.78 Million by 2030, says Business Market Insights.
According to Business Market Insights' research, the Europe upstream bioprocessing market was valued at US$ 2,581.59 million in 2022 and is expected to reach US$ 7,069.78 million by 2030, registering a CAGR of 13.4% from 2022 to 2030. Technological advancements and Rapid growth of pharmaceutical and biotechnology industries are among the critical factors attributed to the Europe upstream bioprocessing market expansion.
The upstream bioprocessing market is experiencing a wave of technological advancements, presenting considerable industry opportunities. These advancements include innovative developments in cell culture systems, bioreactor design, process monitoring, and control, as well as the integration of automation and digitalization. In September 2023, Repligen Corporation and Sartorius introduced an integrated bioreactor system. Repligen's XCell Alternating Tangential Flow (ATF) upstream intensification technology has been integrated into the Sartorius Biostat stirred-tank reactor (STR). This bioreactor technology is designed to make the application of N perfusion and intensified seed train easier for biopharmaceutical firms. An embedded XCell ATF hardware and software module that combines integrated process analytical technologies with predefined advanced control recipes is incorporated into Biostat STR. This module is intended to simplify the management of cell growth and enhance cell retention in perfusion procedures, eliminating the need for a separate cell retention control tower. Such modern products feature enhanced process efficiency, scalability, and adaptability, which are crucial for meeting the evolving demands of biopharmaceutical production.
Advanced cell culture media formulations and next-generation bioreactor technologies are contributing to the optimization of upstream bioprocessing, in turn, enabling higher product yields, improved product quality, and the efficient production of complex biologics. The ongoing integration of advanced analytics and real-time process monitoring is revolutionizing data-driven decision-making in bioprocessing, driving precision and process optimization opportunities. Progress in biotechnology also fosters the development of flexible and modular manufacturing platforms. Additionally, the convergence of machine learning, artificial intelligence, and predictive analytics is paving the way for predictive bioprocessing, thereby unlocking proactive process control, quality assurance, and cost optimization opportunities. Thus, technological advancements in upstream bioprocessing are reshaping the industry, presenting new avenues for innovation, efficiency, and adaptability.
On the contrary, stringent regulatory framework hampers the growth of Europe upstream bioprocessing market.
Based on product type, the Europe upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.0% market share in 2022, amassing US$ 902.31 million. It is projected to garner US$ 2,444.28 million by 2030 to expand at 13.3% CAGR during 2022-2030.
Based on workflow, the Europe upstream bioprocessing market is segmented into media preparation, cell culture, and cell separation. The cell separation segment held 41.2% share of Europe upstream bioprocessing market in 2022, amassing US$ 1,063.62 million. It is projected to garner US$ 3,016.31 million by 2030 to expand at 13.9% CAGR during 2022-2030.
By usage type, the Europe upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use segment held 55.1% share of Europe upstream bioprocessing market in 2022, amassing US$ 1,421.76 million. It is projected to garner US$ 3,982.50 million by 2030 to expand at 13.7% CAGR during 2022-2030.
In terms of mode, the Europe upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 53.9% share of Europe upstream bioprocessing market in 2022, amassing US$ 1,390.44 million. It is projected to garner US$ 3,718.94 million by 2030 to expand at 13.1% CAGR during 2022-2030.
Based on country, the Europe upstream bioprocessing market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 25.4% share of Europe upstream bioprocessing market in 2022. It was assessed at US$ 655.72 million in 2022 and is likely to hit US$ 1,847.73 million by 2030, exhibiting a CAGR of 13.8% during 2022-2030.
Key players operating in the Europe upstream bioprocessing market are Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Cellexus International Ltd, Sartorius AG, Getinge AB, Merck KGaA, Corning Inc, and Entegris Inc, among others.
- In December 2023, Merck has acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. Merck's upstream therapeutic protein portfolio is boosted by the purchase, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.
- In October 2023, Getinge AB acquired High Purity New England, Inc for US$ 120 million. By the end of 2024, the company will fully integrate High Purity New England, Inc. The acquisition has helped Getinge AB acquire a comprehensive range of proprietary and distributed products from drug discovery, upstream and downstream processing, and fill-and-finish.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com